Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
Inhibikase Therapeutics第四季度每股收益美元（0.64美元）超過預期（0.85美元），銷售額低於同比6.357萬美元
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.85) by 24.71 percent. This is a 37.25 percent increase over losses of $(1.02) per share from the same period last year. The company reported $1.00 thousand in sales this quarter. This is a 98.43 percent decrease over sales of $63.57 thousand the same period last year.
Inhibikase Therapeutics（納斯達克股票代碼：IKT）公佈的季度虧損爲每股0.64美元（0.64美元），比分析師共識估計的美元（0.85美元）高出24.71％。與去年同期每股虧損1.02美元（1.02）相比，增長了37.25％。該公司報告本季度銷售額爲1,000美元。這比去年同期的63,570美元的銷售額下降了98.43％。